proxyvotesnow.com

Home › Companies › UroGen Pharma Ltd. › 2025-2026

UroGen Pharma Ltd. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and UroGen Pharma Ltd.’s Form 8-K, filed 2026-06-23 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 25Reported items
  • 220Asset managers
  • 3,217Fund votes
  • 2026-06-22Main meeting date

Proxy season: 2024-2025 2025-2026

Explore UroGen Pharma Ltd. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by UroGen Pharma Ltd.

These tallies are UroGen Pharma Ltd.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-23 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX. UroGen Pharma Ltd. reported 2 meetings in this season; each is tabulated separately below, with its own filing.

UroGen Pharma Ltd. — official shareholder meeting results, meeting held 2026-06-22 (Form 8-K, filed 2026-06-23)
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Arie Belldegrun, M.D. 23,369,7264,959,9686,330 --8,540,308 Majority: yes
Elect Director: Elizabeth Barrett 25,942,0722,389,2324,720 --8,540,308 Majority: yes
Elect Director: Cynthia M. Butitta 26,378,8381,940,27316,913 --8,540,308 Majority: yes
Elect Director: Stuart Holden, M.D. 26,641,5391,687,8766,609 --8,540,308 Majority: yes
Elect Director: James A. Robinson, Jr. 27,918,601407,39010,033 --8,540,308 Majority: yes
Elect Director: Leana S. Wen, M.D., M.Sc. 26,667,1461,652,27016,608 --8,540,308 Majority: yes
Elect Director: Daniel G. Wildman 27,862,621453,36620,037 --8,540,308 Majority: yes
Proposal 2: Amended and Restated Articles of Association 19,306,2229,007,52822,274 --8,540,308 Majority: yes
Proposal 3 - Compensation Policy Amendment. The shareholders approved the Compensation Policy Amendment. 26,089,4182,182,01764,589 --8,540,308 Majority: yes
Proposal 4 - 2017 Equity Incentive Plan. The shareholders approved the 2017 Amended Plan. 25,204,6443,058,91272,468 --8,540,308 Majority: yes
Proposal 5 - Advisory vote on the compensation of the Company ' s named executive officers. On an advisory basis, the shareholders approved the compensation paid to the Company's named executive officers, as disclosed in the Proxy Statement 25,125,8463,186,04024,138 --8,540,308 Majority: yes
Proposal 6 - E ngagement of PricewaterhouseCoopers LLP as the Company's independent auditor. The shareholders approved the engagement of PricewaterhouseCoopers LLP as the Company's independent auditor until the Company's 2027 annual meeting 36,778,50990,7997,024 ---- Majority: yes

Source: UroGen Pharma Ltd., Form 8-K, filed with the SEC on 2026-06-23 — read the filing on EDGAR.

UroGen Pharma Ltd. — official shareholder meeting results, meeting held 2025-08-26 (Form 8-K, filed 2025-08-27)
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Arie Belldegrun, M.D. 19,945,910---- 1,978,01411,505,228 Majority: yes
Elect Director: Elizabeth Barrett 19,767,638---- 2,156,28711,505,228 Majority: yes
Elect Director: Cynthia M. Butitta 21,606,978---- 316,94711,505,228 Majority: yes
Elect Director: Stuart Holden, M.D. 21,653,905---- 270,02011,505,228 Majority: yes
Elect Director: James A. Robinson, Jr. 21,685,524---- 238,40111,505,228 Majority: yes
Elect Director: Leana S. Wen, M.D., M.Sc. 21,231,727---- 692,19811,505,228 Majority: yes
Elect Director: Daniel G. Wildman 21,700,880---- 223,04511,505,228 Majority: yes
Proposal 2: Amended and Restated Director and Officer Compensation Policy 17,894,9863,295,431733,507 --11,505,228 Majority: yes
Proposal 3 - 2017 Amended Plan. The shareholders approved the 2017 Amended Plan. 18,403,1752,777,281743,465 --11,505,228 Majority: yes
Proposal 4 - Advisory vote on the compensation of the Company ' s named executive officers. On an advisory basis, the shareholders approved the compensation paid to the Company's named executive officers, as disclosed in the Proxy Statement 18,852,9282,217,830853,164 --11,505,228 Majority: yes
Proposal 5: Advisory vote on the frequency of shareholder advisory votes on the compensation of the Company ' s named executive officers 32,922,800136,141233,650 ---- Majority: yes

Source: UroGen Pharma Ltd., Form 8-K, filed with the SEC on 2025-08-27 — read the filing on EDGAR.

How asset managers voted at the UroGen Pharma Ltd. 2025-2026 meetings

Each item below shows how the 220 asset managers that disclosed a UroGen Pharma Ltd. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of UroGen Pharma Ltd.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Meeting held 2026-06-22.

Combines 8 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%11%
FOR: 25,125,846AGAINST: 3,186,040

UroGen Pharma Ltd.’s own tally for this item (“Proposal 5 - Advisory vote on the compensation of the Company ' s named executive officers. On an advisory basis, the shareholders approved the compensation paid to the Company's named executive officers, as disclosed in”): 25,125,846 for, 3,186,040 against, per its Form 8-K filed 2026-06-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 48,708,280 outstanding shares: 51.6% for, 7% against (58% of the company cast a for/against vote).

The 200 asset managers below cast 88% of the shares they voted on this item FOR (21,381,675 for, 2,887,120 against).

FOR 82%11%7%
FOR: 21,381,675 (81.6%)AGAINST: 2,887,120 (11.0%)ABSTAIN: 1,927,357 (7.4%)NOT VOTED: 2,000 (0.0%)
Largest asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at UroGen Pharma Ltd., 2025-2026
Asset managerForAgainst AbstainWithheldVote
RTW INVESTMENTS, LP4,543,8950 00For
American Century2,036,6640 00For
Kynam Capital Management, LP00 1,923,4100Abstain
BlackRock1,650,8346,273 00For
MENORA MIVTACHIM HOLDINGS LTD.01,145,329 00Against
ORBIMED ADVISORS LLC903,7160 00For
MPM BioImpact LLC897,9180 00For
DE Shaw897,1050 00For
SILVERARC CAPITAL MANAGEMENT, LLC822,1120 00For
Fidelity818,8450 00For
Candriam S.C.A.0782,553 00Against
Migdal Insurance & Financial Holdings Ltd.0770,908 00Against
ACORN CAPITAL ADVISORS, LLC702,8370 00For
FRONTIER CAPITAL MANAGEMENT CO LLC647,01017,766 00For
Vanguard619,0875 00For
GEODE CAPITAL MANAGEMENT, LLC518,4880 00For
Soleus Capital Management, L.P.447,0000 00For
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND387,0740 00For
Point72373,0490 00For
J. Goldman & Co LP356,5770 00For
State Street353,290778 00For
Woodline Partners LP349,7610 00For
Ally Bridge Group (NY) LLC302,4330 00For
SUPERSTRING CAPITAL MANAGEMENT LP277,5370 00For
RICE HALL JAMES & ASSOCIATES, LLC274,1140 00For

Showing the 25 largest of 200 asset managers. See all 200 in the interactive database.

2. To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of the Company's named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Meeting held 2025-08-26.

Combines 5 wordings of this item as funds reported it.

99.5% Majority: yes · of votes cast

FOR 99.5%
FOR: 32,922,800AGAINST: 136,141

UroGen Pharma Ltd.’s own tally for this item (“Proposal 5: Advisory vote on the frequency of shareholder advisory votes on the compensation of the Company ' s named executive officers”): 32,922,800 for, 136,141 against, per its Form 8-K filed 2025-08-27 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 48,708,280 outstanding shares: 68% for, 0.3% against (68% of the company cast a for/against vote).

The 145 asset managers below cast 99.1% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

ABSTAIN 56%ONE YEAR 28%1 YEAR 15%
FOR: 0.1%AGAINST: 0.0%ABSTAIN: 55.7%ONE YEAR: 28.1%1 YEAR: 15.2%1-YEAR: 0.9%1: 0.0%3 YEARS: 0.0%
Largest asset managers voting on “To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation o” at UroGen Pharma Ltd., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Kynam Capital Management, LP00 18,064,4520Abstain
RTW INVESTMENTS, LP00 00One Year
Soleus Capital Management, L.P.00 001 Year
SILVERARC CAPITAL MANAGEMENT, LLC00 00One Year
BlackRock00 001 Year
T. Rowe Price00 00One Year
ADAGE CAPITAL PARTNERS GP, L.L.C.00 00One Year
Wildcat Capital Management, LLC00 495,6060Abstain
ORBIMED ADVISORS LLC00 001 Year
Point7200 00One Year
DAFNA Capital Management LLC00 001 Year
State Street00 00One Year
Woodline Partners LP00 001-Year
Citadel00 00One Year
RICE HALL JAMES & ASSOCIATES, LLC00 001 Year
Fidelity00 00One Year
ARK ETF Trust00 001 Year
GEODE CAPITAL MANAGEMENT, LLC00 00One Year
Northern Trust00 001 Year
PANAGORA ASSET MANAGEMENT INC00 00One Year
Two Sigma00 00One Year
AQR00 00One Year
Wellington00 001 Year
WELLS FARGO CLEARING SERVICES, LLC00 001 Year
Allianz00 00One Year

Showing the 25 largest of 145 asset managers. See all 145 in the interactive database.

3. To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Meeting held 2025-08-26.

Combines 6 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%11%
FOR: 18,852,928AGAINST: 2,217,830

UroGen Pharma Ltd.’s own tally for this item (“Proposal 4 - Advisory vote on the compensation of the Company ' s named executive officers. On an advisory basis, the shareholders approved the compensation paid to the Company's named executive officers, as disclosed in”): 18,852,928 for, 2,217,830 against, per its Form 8-K filed 2025-08-27 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 48,708,280 outstanding shares: 39% for, 5% against (43% of the company cast a for/against vote).

The 122 asset managers below cast 89% of the shares they voted on this item FOR (10,320,634 for, 1,244,913 against).

FOR 85%10%
FOR: 10,320,634 (84.8%)AGAINST: 1,244,913 (10.2%)ABSTAIN: 603,246 (5.0%)
Largest asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at UroGen Pharma Ltd., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Soleus Capital Management, L.P.1,885,0000 00For
BlackRock1,422,3612,772 00For
SILVERARC CAPITAL MANAGEMENT, LLC1,395,3500 00For
MENORA MIVTACHIM HOLDINGS LTD.01,145,299 00Against
T. Rowe Price634,0080 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.536,6000 00For
Wildcat Capital Management, LLC00 495,6060Abstain
ORBIMED ADVISORS LLC478,4000 00For
Point72450,0120 00For
DAFNA Capital Management LLC349,5150 00For
State Street311,457146 00For
Woodline Partners LP306,7240 00For
Citadel262,7910 00For
RICE HALL JAMES & ASSOCIATES, LLC215,0810 00For
Fidelity166,1080 00For
ARK ETF Trust166,0940 00For
GEODE CAPITAL MANAGEMENT, LLC165,8440 00For
Northern Trust132,3460 00For
PANAGORA ASSET MANAGEMENT INC127,4360 00For
Two Sigma121,9970 00For
AQR116,5490 00For
Wellington103,9680 00For
Kynam Capital Management, LP00 102,8370Abstain
WELLS FARGO CLEARING SERVICES, LLC94,3490 00For
SUPERSTRING CAPITAL MANAGEMENT LP87,9120 00For

Showing the 25 largest of 122 asset managers. See all 122 in the interactive database.

4. TO APPROVE AN AMENDMENT TO THE COMPANY'S AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR AND OFFICER COMPENSATION POLICY IN RELATION TO DIRECTORS' AND OFFICERS' INSURANCE.

COMPENSATIONMajority of the votes cast: yes

Meeting held 2026-06-22.

Combines 4 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%8%
FOR: 26,089,418AGAINST: 2,182,017

UroGen Pharma Ltd.’s own tally for this item (“Proposal 3 - Compensation Policy Amendment. The shareholders approved the Compensation Policy Amendment.”): 26,089,418 for, 2,182,017 against, per its Form 8-K filed 2026-06-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 48,708,280 outstanding shares: 53.6% for, 4% against (58% of the company cast a for/against vote).

The 50 asset managers below cast 88% of the shares they voted on this item FOR (5,492,439 for, 770,911 against).

FOR 88%12%
FOR: 5,492,439 (87.6%)AGAINST: 770,911 (12.3%)ABSTAIN: 3,947 (0.1%)
Largest asset managers voting on “TO APPROVE AN AMENDMENT TO THE COMPANY'S AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR AND OFFICER COMPENSATION P” at UroGen Pharma Ltd., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock1,656,8210 00For
American Century902,5290 00For
Migdal Insurance & Financial Holdings Ltd.0770,908 00Against
ACORN CAPITAL ADVISORS, LLC702,8370 00For
Fidelity650,6110 00For
Vanguard542,2473 00For
AIG/SunAmerica114,0620 00For
ARK ETF Trust101,5080 00For
Charles Schwab88,4180 00For
Equitable83,8020 00For
TIAA82,9880 00For
Tema ETF Trust74,2740 00For
QUANTITATIVE MASTER SERIES LLC62,3330 00For
CLEARWATER INVESTMENT TRUST61,2740 00For
Lincoln Financial41,8690 00For
NORTHERN LIGHTS FUND TRUST II38,8210 00For
Northern Trust30,4380 00For
Amplify ETF Trust29,2840 00For
Goldman Sachs28,3500 00For
Russell Investments24,8130 00For
Brighthouse14,0180 3,9470For
Global X17,4620 00For
MASTER INVESTMENT PORTFOLIO17,0340 00For
State Street15,0080 00For
TRUST FOR PROFESSIONAL MANAGERS14,6070 00For

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

5. To elect to the Board of Directors each of the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Arie Belldegrun, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-22.

Combines 3 wordings of this item as funds reported it.

82% Majority: yes · of votes cast

FOR 82%AGAINST 18%
FOR: 23,369,726AGAINST: 4,959,968

UroGen Pharma Ltd.’s own tally for this item (“Elect Director: Arie Belldegrun, M.D.”): 23,369,726 for, 4,959,968 against, per its Form 8-K filed 2026-06-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 48,708,280 outstanding shares: 48.0% for, 10% against (58% of the company cast a for/against vote).

The 47 asset managers below cast 65% of the shares they voted on this item FOR (2,636,797 for, 1,429,400 against).

FOR 65%AGAINST 35%
FOR: 2,636,797 (64.8%)AGAINST: 1,429,400 (35.1%)ABSTAIN: 3,947 (0.1%)
Largest asset managers voting on “To elect to the Board of Directors each of the following seven nominees presented by the Board of Directors to” at UroGen Pharma Ltd., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock110,892822,525 00Against
American Century902,5290 00For
Fidelity632,57818,033 00For
Vanguard374,302167,947 00For
AIG/SunAmerica114,0620 00For
ARK ETF Trust101,5080 00For
Charles Schwab088,418 00Against
Equitable21,11062,692 00Against
TIAA82,9880 00For
Tema ETF Trust74,2740 00For
QUANTITATIVE MASTER SERIES LLC062,333 00Against
CLEARWATER INVESTMENT TRUST061,274 00Against
Lincoln Financial41,8690 00For
NORTHERN LIGHTS FUND TRUST II1,76937,052 00Against
Northern Trust30,4380 00For
Amplify ETF Trust029,284 00Against
Goldman Sachs28,3500 00For
Russell Investments024,813 00Against
Brighthouse14,0180 3,9470For
Global X017,462 00Against
MASTER INVESTMENT PORTFOLIO17,0340 00For
State Street15,0080 00For
TRUST FOR PROFESSIONAL MANAGERS14,6070 00For
Pacific Life013,742 00Against
John Hancock9,8830 00For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

6. To elect to the Board of Directors each of the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Cynthia M. Butitta

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-22.

Combines 3 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%
FOR: 26,378,838AGAINST: 1,940,273

UroGen Pharma Ltd.’s own tally for this item (“Elect Director: Cynthia M. Butitta”): 26,378,838 for, 1,940,273 against, per its Form 8-K filed 2026-06-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 48,708,280 outstanding shares: 54.2% for, 4% against (58% of the company cast a for/against vote).

The 47 asset managers below cast 99.2% of the shares they voted on this item FOR (4,035,998 for, 30,200 against).

FOR 99.1%
FOR: 4,035,998 (99.2%)AGAINST: 30,200 (0.7%)ABSTAIN: 3,947 (0.1%)
Largest asset managers voting on “To elect to the Board of Directors each of the following seven nominees presented by the Board of Directors to” at UroGen Pharma Ltd., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock933,4170 00For
American Century902,5290 00For
Fidelity650,6110 00For
Vanguard541,563687 00For
AIG/SunAmerica114,0620 00For
ARK ETF Trust101,5080 00For
Charles Schwab88,4180 00For
Equitable83,8020 00For
TIAA82,9880 00For
Tema ETF Trust74,2740 00For
QUANTITATIVE MASTER SERIES LLC62,3330 00For
CLEARWATER INVESTMENT TRUST61,2740 00For
Lincoln Financial41,8690 00For
NORTHERN LIGHTS FUND TRUST II38,8210 00For
Northern Trust30,4380 00For
Amplify ETF Trust029,284 00Against
Goldman Sachs28,3500 00For
Russell Investments24,8130 00For
Brighthouse14,0180 3,9470For
Global X17,4620 00For
MASTER INVESTMENT PORTFOLIO17,0340 00For
State Street15,0080 00For
TRUST FOR PROFESSIONAL MANAGERS14,6070 00For
Pacific Life13,7420 00For
John Hancock9,8830 00For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

7. To elect to the Board of Directors each of the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Daniel G. Wildman

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-22.

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 27,862,621AGAINST: 453,366

UroGen Pharma Ltd.’s own tally for this item (“Elect Director: Daniel G. Wildman”): 27,862,621 for, 453,366 against, per its Form 8-K filed 2026-06-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 48,708,280 outstanding shares: 57% for, 1.0% against (58% of the company cast a for/against vote).

The 47 asset managers below cast 99.9% of the shares they voted on this item FOR (4,066,197 for, 1 against).

FOR 99.9%
FOR: 4,066,197 (99.9%)AGAINST: 1 (0.0%)ABSTAIN: 3,947 (0.1%)
Largest asset managers voting on “To elect to the Board of Directors each of the following seven nominees presented by the Board of Directors to” at UroGen Pharma Ltd., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock933,4170 00For
American Century902,5290 00For
Fidelity650,6110 00For
Vanguard542,2491 00For
AIG/SunAmerica114,0620 00For
ARK ETF Trust101,5080 00For
Charles Schwab88,4180 00For
Equitable83,8020 00For
TIAA82,9880 00For
Tema ETF Trust74,2740 00For
QUANTITATIVE MASTER SERIES LLC62,3330 00For
CLEARWATER INVESTMENT TRUST61,2740 00For
Lincoln Financial41,8690 00For
NORTHERN LIGHTS FUND TRUST II38,8210 00For
Northern Trust30,4380 00For
Amplify ETF Trust29,2840 00For
Goldman Sachs28,3500 00For
Russell Investments24,8130 00For
Brighthouse14,0180 3,9470For
Global X17,4620 00For
MASTER INVESTMENT PORTFOLIO17,0340 00For
State Street15,0080 00For
TRUST FOR PROFESSIONAL MANAGERS14,6070 00For
Pacific Life13,7420 00For
John Hancock9,8830 00For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

8. To elect to the Board of Directors each of the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Elizabeth Barrett

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-22.

Combines 3 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%8%
FOR: 25,942,072AGAINST: 2,389,232

UroGen Pharma Ltd.’s own tally for this item (“Elect Director: Elizabeth Barrett”): 25,942,072 for, 2,389,232 against, per its Form 8-K filed 2026-06-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 48,708,280 outstanding shares: 53.3% for, 5% against (58% of the company cast a for/against vote).

The 47 asset managers below cast 99.2% of the shares they voted on this item FOR (4,035,998 for, 30,200 against).

FOR 99.1%
FOR: 4,035,998 (99.2%)AGAINST: 30,200 (0.7%)ABSTAIN: 3,947 (0.1%)
Largest asset managers voting on “To elect to the Board of Directors each of the following seven nominees presented by the Board of Directors to” at UroGen Pharma Ltd., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock933,4170 00For
American Century902,5290 00For
Fidelity650,6110 00For
Vanguard541,563687 00For
AIG/SunAmerica114,0620 00For
ARK ETF Trust101,5080 00For
Charles Schwab88,4180 00For
Equitable83,8020 00For
TIAA82,9880 00For
Tema ETF Trust74,2740 00For
QUANTITATIVE MASTER SERIES LLC62,3330 00For
CLEARWATER INVESTMENT TRUST61,2740 00For
Lincoln Financial41,8690 00For
NORTHERN LIGHTS FUND TRUST II38,8210 00For
Northern Trust30,4380 00For
Amplify ETF Trust029,284 00Against
Goldman Sachs28,3500 00For
Russell Investments24,8130 00For
Brighthouse14,0180 3,9470For
Global X17,4620 00For
MASTER INVESTMENT PORTFOLIO17,0340 00For
State Street15,0080 00For
TRUST FOR PROFESSIONAL MANAGERS14,6070 00For
Pacific Life13,7420 00For
John Hancock9,8830 00For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

9. To elect to the Board of Directors each of the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: James A. Robinson, Jr.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-22.

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 27,918,601AGAINST: 407,390

UroGen Pharma Ltd.’s own tally for this item (“Elect Director: James A. Robinson, Jr.”): 27,918,601 for, 407,390 against, per its Form 8-K filed 2026-06-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 48,708,280 outstanding shares: 57% for, 0.9% against (58% of the company cast a for/against vote).

The 47 asset managers below cast 99.9% of the shares they voted on this item FOR (4,062,331 for, 3,867 against).

FOR 99.8%
FOR: 4,062,331 (99.8%)AGAINST: 3,867 (0.1%)ABSTAIN: 3,947 (0.1%)
Largest asset managers voting on “To elect to the Board of Directors each of the following seven nominees presented by the Board of Directors to” at UroGen Pharma Ltd., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock933,4170 00For
American Century902,5290 00For
Fidelity650,6110 00For
Vanguard542,2491 00For
AIG/SunAmerica114,0620 00For
ARK ETF Trust101,5080 00For
Charles Schwab88,4180 00For
Equitable83,8020 00For
TIAA82,9880 00For
Tema ETF Trust74,2740 00For
QUANTITATIVE MASTER SERIES LLC62,3330 00For
CLEARWATER INVESTMENT TRUST61,2740 00For
Lincoln Financial41,8690 00For
NORTHERN LIGHTS FUND TRUST II38,8210 00For
Northern Trust30,4380 00For
Amplify ETF Trust29,2840 00For
Goldman Sachs28,3500 00For
Russell Investments24,8130 00For
Brighthouse14,0180 3,9470For
Global X17,4620 00For
MASTER INVESTMENT PORTFOLIO17,0340 00For
State Street15,0080 00For
TRUST FOR PROFESSIONAL MANAGERS14,6070 00For
Pacific Life13,7420 00For
John Hancock9,8830 00For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

10. To elect to the Board of Directors each of the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Leana S. Wen, M.D., M.Sc.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-22.

Combines 3 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 26,667,146AGAINST: 1,652,270

UroGen Pharma Ltd.’s own tally for this item (“Elect Director: Leana S. Wen, M.D., M.Sc.”): 26,667,146 for, 1,652,270 against, per its Form 8-K filed 2026-06-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 48,708,280 outstanding shares: 54.7% for, 3% against (58% of the company cast a for/against vote).

The 47 asset managers below cast 92% of the shares they voted on this item FOR (3,743,693 for, 322,504 against).

FOR 92%8%
FOR: 3,743,693 (92.0%)AGAINST: 322,504 (7.9%)ABSTAIN: 3,947 (0.1%)
Largest asset managers voting on “To elect to the Board of Directors each of the following seven nominees presented by the Board of Directors to” at UroGen Pharma Ltd., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock933,4170 00For
American Century902,5290 00For
Fidelity650,6110 00For
Vanguard374,991167,258 00For
AIG/SunAmerica114,0620 00For
ARK ETF Trust101,5080 00For
Charles Schwab88,4180 00For
Equitable83,8020 00For
TIAA82,9880 00For
Tema ETF Trust74,2740 00For
QUANTITATIVE MASTER SERIES LLC62,3330 00For
CLEARWATER INVESTMENT TRUST061,274 00Against
Lincoln Financial41,8690 00For
NORTHERN LIGHTS FUND TRUST II1,76937,052 00Against
Northern Trust30,4380 00For
Amplify ETF Trust29,2840 00For
Goldman Sachs28,3500 00For
Russell Investments024,813 00Against
Brighthouse14,0180 3,9470For
Global X017,462 00Against
MASTER INVESTMENT PORTFOLIO17,0340 00For
State Street15,0080 00For
TRUST FOR PROFESSIONAL MANAGERS14,6070 00For
Pacific Life13,7420 00For
John Hancock9,8830 00For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

11. To elect to the Board of Directors each of the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Stuart Holden, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-22.

Combines 3 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 26,641,539AGAINST: 1,687,876

UroGen Pharma Ltd.’s own tally for this item (“Elect Director: Stuart Holden, M.D.”): 26,641,539 for, 1,687,876 against, per its Form 8-K filed 2026-06-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 48,708,280 outstanding shares: 54.7% for, 3% against (58% of the company cast a for/against vote).

The 47 asset managers below cast 99.2% of the shares they voted on this item FOR (4,035,999 for, 30,199 against).

FOR 99.1%
FOR: 4,035,999 (99.2%)AGAINST: 30,199 (0.7%)ABSTAIN: 3,947 (0.1%)
Largest asset managers voting on “To elect to the Board of Directors each of the following seven nominees presented by the Board of Directors to” at UroGen Pharma Ltd., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock933,4170 00For
American Century902,5290 00For
Fidelity650,6110 00For
Vanguard541,564686 00For
AIG/SunAmerica114,0620 00For
ARK ETF Trust101,5080 00For
Charles Schwab88,4180 00For
Equitable83,8020 00For
TIAA82,9880 00For
Tema ETF Trust74,2740 00For
QUANTITATIVE MASTER SERIES LLC62,3330 00For
CLEARWATER INVESTMENT TRUST61,2740 00For
Lincoln Financial41,8690 00For
NORTHERN LIGHTS FUND TRUST II38,8210 00For
Northern Trust30,4380 00For
Amplify ETF Trust029,284 00Against
Goldman Sachs28,3500 00For
Russell Investments24,8130 00For
Brighthouse14,0180 3,9470For
Global X17,4620 00For
MASTER INVESTMENT PORTFOLIO17,0340 00For
State Street15,0080 00For
TRUST FOR PROFESSIONAL MANAGERS14,6070 00For
Pacific Life13,7420 00For
John Hancock9,8830 00For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

12. TO APPROVE AN AMENDMENT TO THE COMPANY'S 2017 EQUITY INCENTIVE PLAN TO INCREASE THE NUMBER OF ORDINARY SHARES AUTHORIZED FOR ISSUANCE UNDER THE PLAN BY 1,000,000 SHARES.

COMPENSATIONMajority of the votes cast: yes

Meeting held 2026-06-22.

89% Majority: yes · of votes cast

FOR 89%11%
FOR: 25,204,644AGAINST: 3,058,912

UroGen Pharma Ltd.’s own tally for this item (“Proposal 4 - 2017 Equity Incentive Plan. The shareholders approved the 2017 Amended Plan.”): 25,204,644 for, 3,058,912 against, per its Form 8-K filed 2026-06-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 48,708,280 outstanding shares: 51.7% for, 6% against (58% of the company cast a for/against vote).

The 47 asset managers below cast 77% of the shares they voted on this item FOR (3,118,862 for, 947,336 against).

FOR 77%AGAINST 23%
FOR: 3,118,862 (76.6%)AGAINST: 947,336 (23.3%)ABSTAIN: 3,947 (0.1%)
Largest asset managers voting on “TO APPROVE AN AMENDMENT TO THE COMPANY'S 2017 EQUITY INCENTIVE PLAN TO INCREASE THE NUMBER OF ORDINARY SHARES ” at UroGen Pharma Ltd., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock933,4170 00For
American Century0902,529 00Against
Fidelity650,6110 00For
Vanguard541,563687 00For
AIG/SunAmerica114,0620 00For
ARK ETF Trust101,5080 00For
Charles Schwab88,4180 00For
Equitable83,8020 00For
TIAA82,9880 00For
Tema ETF Trust74,2740 00For
QUANTITATIVE MASTER SERIES LLC62,3330 00For
CLEARWATER INVESTMENT TRUST61,2740 00For
Lincoln Financial41,8690 00For
NORTHERN LIGHTS FUND TRUST II38,8210 00For
Northern Trust30,4380 00For
Amplify ETF Trust029,284 00Against
Goldman Sachs28,3500 00For
Russell Investments24,8130 00For
Brighthouse14,0180 3,9470For
Global X17,4620 00For
MASTER INVESTMENT PORTFOLIO17,0340 00For
State Street15,0080 00For
TRUST FOR PROFESSIONAL MANAGERS014,607 00Against
Pacific Life13,7420 00For
John Hancock9,8830 00For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

13. To approve the engagement of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as the Company's auditor until the Company's 2027 annual meeting of shareholders.

AUDIT-RELATEDMajority of the votes cast: yes

Meeting held 2026-06-22.

Combines 2 wordings of this item as funds reported it.

99.7% Majority: yes · of votes cast

FOR 99.7%
FOR: 36,778,509AGAINST: 90,799

UroGen Pharma Ltd.’s own tally for this item (“Proposal 6 - E ngagement of PricewaterhouseCoopers LLP as the Company's independent auditor. The shareholders approved the engagement of PricewaterhouseCoopers LLP as the Company's independent auditor until the Company's”): 36,778,509 for, 90,799 against, per its Form 8-K filed 2026-06-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 48,708,280 outstanding shares: 76% for, 0.2% against (76% of the company cast a for/against vote).

The 47 asset managers below cast 100% of the shares they voted on this item FOR (4,066,198 for, 0 against).

FOR 99.9%
FOR: 4,066,198 (99.9%)ABSTAIN: 3,947 (0.1%)
Largest asset managers voting on “To approve the engagement of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as ” at UroGen Pharma Ltd., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock933,4170 00For
American Century902,5290 00For
Fidelity650,6110 00For
Vanguard542,2500 00For
AIG/SunAmerica114,0620 00For
ARK ETF Trust101,5080 00For
Charles Schwab88,4180 00For
Equitable83,8020 00For
TIAA82,9880 00For
Tema ETF Trust74,2740 00For
QUANTITATIVE MASTER SERIES LLC62,3330 00For
CLEARWATER INVESTMENT TRUST61,2740 00For
Lincoln Financial41,8690 00For
NORTHERN LIGHTS FUND TRUST II38,8210 00For
Northern Trust30,4380 00For
Amplify ETF Trust29,2840 00For
Goldman Sachs28,3500 00For
Russell Investments24,8130 00For
Brighthouse14,0180 3,9470For
Global X17,4620 00For
MASTER INVESTMENT PORTFOLIO17,0340 00For
State Street15,0080 00For
TRUST FOR PROFESSIONAL MANAGERS14,6070 00For
Pacific Life13,7420 00For
John Hancock9,8830 00For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

14. TO APPROVE THE AMENDMENT AND RESTATEMENT OF THE ARTICLES OF ASSOCIATION OF THE COMPANY TO, AMONG OTHER THINGS, TIE ELIGIBILITY FOR SHAREHOLDER PROPOSALS TO THE REQUIREMENTS UNDER THE ISRAELI COMPANIES LAW.

SHAREHOLDER RIGHTS AND DEFENSESMajority of the votes cast: yes

Meeting held 2026-06-22.

68% Majority: yes · of votes cast

FOR 68%AGAINST 32%
FOR: 19,306,222AGAINST: 9,007,528

UroGen Pharma Ltd.’s own tally for this item (“Proposal 2: Amended and Restated Articles of Association”): 19,306,222 for, 9,007,528 against, per its Form 8-K filed 2026-06-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 48,708,280 outstanding shares: 40% for, 18% against (58% of the company cast a for/against vote).

The 41 asset managers below cast 49.6% of the shares they voted on this item FOR (1,813,722 for, 1,845,530 against).

FOR 49.6%AGAINST 50.4%
FOR: 1,813,722 (49.6%)AGAINST: 1,845,530 (50.4%)
Largest asset managers voting on “TO APPROVE THE AMENDMENT AND RESTATEMENT OF THE ARTICLES OF ASSOCIATION OF THE COMPANY TO, AMONG OTHER THINGS,” at UroGen Pharma Ltd., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock822,525110,892 00For
American Century0902,529 00Against
Fidelity184,227466,384 00Against
Vanguard373,170695 00For
AIG/SunAmerica0114,062 00Against
ARK ETF Trust101,5080 00For
Equitable62,69221,110 00For
TIAA082,988 00Against
Tema ETF Trust74,2740 00For
QUANTITATIVE MASTER SERIES LLC62,3330 00For
Lincoln Financial25,20016,669 00For
Northern Trust30,4380 00For
Amplify ETF Trust029,284 00Against
Goldman Sachs28,3500 00For
MASTER INVESTMENT PORTFOLIO017,034 00Against
State Street15,0080 00For
TRUST FOR PROFESSIONAL MANAGERS014,607 00Against
Brighthouse014,018 00Against
Pacific Life13,7420 00For
John Hancock09,883 00Against
Bridge Builder Trust9,7460 00For
AQR08,349 00Against
ProShares07,916 00Against
Voya06,721 00Against
DWS05,628 00Against

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

15. TO APPROVE AMENDMENTS TO THE COMPANY'S 2024 NON-EMPLOYEE DIRECTOR AND OFFICER COMPENSATION POLICY TO, AMONG OTHER THINGS, INCREASE THE EQUITY COMPENSATION PAYABLE TO OUR EXECUTIVE OFFICERS AND NON-EMPLOYEE DIRECTORS.

COMPENSATIONMajority of the votes cast: yes

Meeting held 2025-08-26.

84% Majority: yes · of votes cast

FOR 84%AGAINST 16%
FOR: 17,894,986AGAINST: 3,295,431

UroGen Pharma Ltd.’s own tally for this item (“Proposal 2: Amended and Restated Director and Officer Compensation Policy”): 17,894,986 for, 3,295,431 against, per its Form 8-K filed 2025-08-27 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 48,708,280 outstanding shares: 37% for, 7% against (44% of the company cast a for/against vote).

The 36 asset managers below cast 98% of the shares they voted on this item FOR (2,585,060 for, 57,887 against).

FOR 98%
FOR: 2,585,060 (97.6%)AGAINST: 57,887 (2.2%)ABSTAIN: 4,803 (0.2%)
Largest asset managers voting on “TO APPROVE AMENDMENTS TO THE COMPANY'S 2024 NON-EMPLOYEE DIRECTOR AND OFFICER COMPENSATION POLICY TO, AMONG OT” at UroGen Pharma Ltd., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock1,425,156261 00For
DAFNA Capital Management LLC349,5150 00For
T. Rowe Price266,2980 00For
ARK ETF Trust166,0940 00For
Fidelity164,4870 00For
Equitable38,1690 00For
Lincoln Financial28,9000 00For
SEI025,960 00Against
Palo Alto Investors LP24,5000 00For
Global X020,065 00Against
MASTER INVESTMENT PORTFOLIO17,5840 00For
Vanguard14,8510 00For
QUANTITATIVE MASTER SERIES LLC14,6000 00For
Pacific Life12,7760 00For
State Street10,5660 00For
ProShares9,9240 00For
Charles Schwab09,276 00Against
Bridge Builder Trust6,0890 00For
Goldman Sachs6,0610 00For
John Hancock5,7670 00For
Brighthouse10 4,8030Abstain
AIG/SunAmerica4,3930 00For
Calvert3,8320 00For
Nationwide3,1620 00For
ALPS ETF Trust3,0340 00For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

16. To elect to the Board of Directors the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Arie Belldegrun, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-08-26.

Combines 4 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%9%
FOR: 19,945,910WITHHELD: 1,978,014

UroGen Pharma Ltd.’s own tally for this item (“Elect Director: Arie Belldegrun, M.D.”): 19,945,910 for, 1,978,014 withheld, per its Form 8-K filed 2025-08-27 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 48,708,280 outstanding shares: 41% for, 4% withheld (45.0% of the company cast a for/withheld vote).

The 34 asset managers below cast 100% of the shares they voted on this item FOR (736,064 for, 0 against).

FOR 49.7%ABSTAIN 50.3%
FOR: 736,064 (49.7%)ABSTAIN: 743,935 (50.3%)
Largest asset managers voting on “To elect to the Board of Directors the following seven nominees presented by the Board of Directors to hold of” at UroGen Pharma Ltd., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock7,4720 624,2090Abstain
T. Rowe Price266,2980 00For
ARK ETF Trust166,0940 00For
Fidelity164,4870 00For
Equitable21,5000 16,6690For
Lincoln Financial28,9000 00For
SEI00 25,9600Abstain
Global X00 20,0650Abstain
MASTER INVESTMENT PORTFOLIO17,5840 00For
Vanguard14,8510 00For
QUANTITATIVE MASTER SERIES LLC00 14,6000Abstain
Pacific Life00 12,7760Abstain
State Street10,5660 00For
ProShares9,9240 00For
Charles Schwab00 9,2760Abstain
Bridge Builder Trust00 6,0890Abstain
Goldman Sachs6,0610 00For
John Hancock5,7670 00For
Brighthouse10 4,8030Abstain
AIG/SunAmerica4,3930 00For
Calvert00 3,8320Abstain
Nationwide00 3,1620Abstain
ALPS ETF Trust3,0340 00For
Northern Trust3,0310 00For
CLEARWATER INVESTMENT TRUST00 2,3250Abstain

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

17. To elect to the Board of Directors the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Cynthia M. Butitta

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-08-26.

Combines 4 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 21,606,978WITHHELD: 316,947

UroGen Pharma Ltd.’s own tally for this item (“Elect Director: Cynthia M. Butitta”): 21,606,978 for, 316,947 withheld, per its Form 8-K filed 2025-08-27 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 48,708,280 outstanding shares: 44% for, 0.7% withheld (45.0% of the company cast a for/withheld vote).

The 34 asset managers below cast 100% of the shares they voted on this item FOR (1,475,027 for, 0 against).

FOR 99.6%
FOR: 1,475,027 (99.7%)ABSTAIN: 4,972 (0.3%)
Largest asset managers voting on “To elect to the Board of Directors the following seven nominees presented by the Board of Directors to hold of” at UroGen Pharma Ltd., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock631,6810 00For
T. Rowe Price266,2980 00For
ARK ETF Trust166,0940 00For
Fidelity164,4870 00For
Equitable38,1690 00For
Lincoln Financial28,9000 00For
SEI25,9600 00For
Global X20,0650 00For
MASTER INVESTMENT PORTFOLIO17,5840 00For
Vanguard14,8510 00For
QUANTITATIVE MASTER SERIES LLC14,6000 00For
Pacific Life12,7760 00For
State Street10,5660 00For
ProShares9,9240 00For
Charles Schwab9,2760 00For
Bridge Builder Trust6,0890 00For
Goldman Sachs6,0610 00For
John Hancock5,7670 00For
Brighthouse10 4,8030Abstain
AIG/SunAmerica4,3930 00For
Calvert3,8320 00For
Nationwide3,1620 00For
ALPS ETF Trust3,0340 00For
Northern Trust3,0310 00For
CLEARWATER INVESTMENT TRUST2,3250 00For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

18. To elect to the Board of Directors the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Daniel G. Wildman

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-08-26.

Combines 4 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 21,700,880WITHHELD: 223,045

UroGen Pharma Ltd.’s own tally for this item (“Elect Director: Daniel G. Wildman”): 21,700,880 for, 223,045 withheld, per its Form 8-K filed 2025-08-27 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 48,708,280 outstanding shares: 45% for, 0.5% withheld (45.0% of the company cast a for/withheld vote).

The 34 asset managers below cast 100% of the shares they voted on this item FOR (1,475,196 for, 0 against).

FOR 99.6%
FOR: 1,475,196 (99.7%)ABSTAIN: 4,803 (0.3%)
Largest asset managers voting on “To elect to the Board of Directors the following seven nominees presented by the Board of Directors to hold of” at UroGen Pharma Ltd., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock631,6810 00For
T. Rowe Price266,2980 00For
ARK ETF Trust166,0940 00For
Fidelity164,4870 00For
Equitable38,1690 00For
Lincoln Financial28,9000 00For
SEI25,9600 00For
Global X20,0650 00For
MASTER INVESTMENT PORTFOLIO17,5840 00For
Vanguard14,8510 00For
QUANTITATIVE MASTER SERIES LLC14,6000 00For
Pacific Life12,7760 00For
State Street10,5660 00For
ProShares9,9240 00For
Charles Schwab9,2760 00For
Bridge Builder Trust6,0890 00For
Goldman Sachs6,0610 00For
John Hancock5,7670 00For
Brighthouse10 4,8030Abstain
AIG/SunAmerica4,3930 00For
Calvert3,8320 00For
Nationwide3,1620 00For
ALPS ETF Trust3,0340 00For
Northern Trust3,0310 00For
CLEARWATER INVESTMENT TRUST2,3250 00For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

19. To elect to the Board of Directors the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Elizabeth Barrett

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-08-26.

Combines 4 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%10%
FOR: 19,767,638WITHHELD: 2,156,287

UroGen Pharma Ltd.’s own tally for this item (“Elect Director: Elizabeth Barrett”): 19,767,638 for, 2,156,287 withheld, per its Form 8-K filed 2025-08-27 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 48,708,280 outstanding shares: 41% for, 4% withheld (45.0% of the company cast a for/withheld vote).

The 34 asset managers below cast 100% of the shares they voted on this item FOR (1,475,027 for, 0 against).

FOR 99.6%
FOR: 1,475,027 (99.7%)ABSTAIN: 4,972 (0.3%)
Largest asset managers voting on “To elect to the Board of Directors the following seven nominees presented by the Board of Directors to hold of” at UroGen Pharma Ltd., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock631,6810 00For
T. Rowe Price266,2980 00For
ARK ETF Trust166,0940 00For
Fidelity164,4870 00For
Equitable38,1690 00For
Lincoln Financial28,9000 00For
SEI25,9600 00For
Global X20,0650 00For
MASTER INVESTMENT PORTFOLIO17,5840 00For
Vanguard14,8510 00For
QUANTITATIVE MASTER SERIES LLC14,6000 00For
Pacific Life12,7760 00For
State Street10,5660 00For
ProShares9,9240 00For
Charles Schwab9,2760 00For
Bridge Builder Trust6,0890 00For
Goldman Sachs6,0610 00For
John Hancock5,7670 00For
Brighthouse10 4,8030Abstain
AIG/SunAmerica4,3930 00For
Calvert3,8320 00For
Nationwide3,1620 00For
ALPS ETF Trust3,0340 00For
Northern Trust3,0310 00For
CLEARWATER INVESTMENT TRUST2,3250 00For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

20. To elect to the Board of Directors the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: James A. Robinson, Jr.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-08-26.

Combines 4 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 21,685,524WITHHELD: 238,401

UroGen Pharma Ltd.’s own tally for this item (“Elect Director: James A. Robinson, Jr.”): 21,685,524 for, 238,401 withheld, per its Form 8-K filed 2025-08-27 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 48,708,280 outstanding shares: 45% for, 0.5% withheld (45.0% of the company cast a for/withheld vote).

The 34 asset managers below cast 100% of the shares they voted on this item FOR (1,471,364 for, 0 against).

FOR 99.4%
FOR: 1,471,364 (99.4%)ABSTAIN: 8,635 (0.6%)
Largest asset managers voting on “To elect to the Board of Directors the following seven nominees presented by the Board of Directors to hold of” at UroGen Pharma Ltd., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock631,6810 00For
T. Rowe Price266,2980 00For
ARK ETF Trust166,0940 00For
Fidelity164,4870 00For
Equitable38,1690 00For
Lincoln Financial28,9000 00For
SEI25,9600 00For
Global X20,0650 00For
MASTER INVESTMENT PORTFOLIO17,5840 00For
Vanguard14,8510 00For
QUANTITATIVE MASTER SERIES LLC14,6000 00For
Pacific Life12,7760 00For
State Street10,5660 00For
ProShares9,9240 00For
Charles Schwab9,2760 00For
Bridge Builder Trust6,0890 00For
Goldman Sachs6,0610 00For
John Hancock5,7670 00For
Brighthouse10 4,8030Abstain
AIG/SunAmerica4,3930 00For
Calvert00 3,8320Abstain
Nationwide3,1620 00For
ALPS ETF Trust3,0340 00For
Northern Trust3,0310 00For
CLEARWATER INVESTMENT TRUST2,3250 00For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

21. To elect to the Board of Directors the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Leana S. Wen, M.D., M.Sc.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-08-26.

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 21,231,727WITHHELD: 692,198

UroGen Pharma Ltd.’s own tally for this item (“Elect Director: Leana S. Wen, M.D., M.Sc.”): 21,231,727 for, 692,198 withheld, per its Form 8-K filed 2025-08-27 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 48,708,280 outstanding shares: 44% for, 1% withheld (45.0% of the company cast a for/withheld vote).

The 34 asset managers below cast 100% of the shares they voted on this item FOR (1,423,014 for, 0 against).

FOR 96%
FOR: 1,423,014 (96.1%)ABSTAIN: 56,985 (3.9%)
Largest asset managers voting on “To elect to the Board of Directors the following seven nominees presented by the Board of Directors to hold of” at UroGen Pharma Ltd., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock631,6810 00For
T. Rowe Price266,2980 00For
ARK ETF Trust166,0940 00For
Fidelity164,4870 00For
Equitable38,1690 00For
Lincoln Financial28,9000 00For
SEI00 25,9600Abstain
Global X00 20,0650Abstain
MASTER INVESTMENT PORTFOLIO17,5840 00For
Vanguard14,8510 00For
QUANTITATIVE MASTER SERIES LLC14,6000 00For
Pacific Life12,7760 00For
State Street10,5660 00For
ProShares9,9240 00For
Charles Schwab9,2760 00For
Bridge Builder Trust6,0890 00For
Goldman Sachs6,0610 00For
John Hancock5,7670 00For
Brighthouse10 4,8030Abstain
AIG/SunAmerica4,3930 00For
Calvert00 3,8320Abstain
Nationwide3,1620 00For
ALPS ETF Trust3,0340 00For
Northern Trust3,0310 00For
CLEARWATER INVESTMENT TRUST00 2,3250Abstain

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

22. To elect to the Board of Directors the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Stuart Holden, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-08-26.

Combines 4 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 21,653,905WITHHELD: 270,020

UroGen Pharma Ltd.’s own tally for this item (“Elect Director: Stuart Holden, M.D.”): 21,653,905 for, 270,020 withheld, per its Form 8-K filed 2025-08-27 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 48,708,280 outstanding shares: 44% for, 0.6% withheld (45.0% of the company cast a for/withheld vote).

The 34 asset managers below cast 100% of the shares they voted on this item FOR (1,475,027 for, 0 against).

FOR 99.6%
FOR: 1,475,027 (99.7%)ABSTAIN: 4,972 (0.3%)
Largest asset managers voting on “To elect to the Board of Directors the following seven nominees presented by the Board of Directors to hold of” at UroGen Pharma Ltd., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock631,6810 00For
T. Rowe Price266,2980 00For
ARK ETF Trust166,0940 00For
Fidelity164,4870 00For
Equitable38,1690 00For
Lincoln Financial28,9000 00For
SEI25,9600 00For
Global X20,0650 00For
MASTER INVESTMENT PORTFOLIO17,5840 00For
Vanguard14,8510 00For
QUANTITATIVE MASTER SERIES LLC14,6000 00For
Pacific Life12,7760 00For
State Street10,5660 00For
ProShares9,9240 00For
Charles Schwab9,2760 00For
Bridge Builder Trust6,0890 00For
Goldman Sachs6,0610 00For
John Hancock5,7670 00For
Brighthouse10 4,8030Abstain
AIG/SunAmerica4,3930 00For
Calvert3,8320 00For
Nationwide3,1620 00For
ALPS ETF Trust3,0340 00For
Northern Trust3,0310 00For
CLEARWATER INVESTMENT TRUST2,3250 00For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

23. TO APPROVE AMENDMENTS TO THE COMPANY'S 2017 EQUITY INCENTIVE PLAN TO, AMONG OTHER THINGS, INCREASE THE NUMBER OF ORDINARY SHARES AUTHORIZED FOR ISSUANCE UNDER THE PLAN BY 2,750,000 SHARES.

COMPENSATIONMajority of the votes cast: yes

Meeting held 2025-08-26.

87% Majority: yes · of votes cast

FOR 87%13%
FOR: 18,403,175AGAINST: 2,777,281

UroGen Pharma Ltd.’s own tally for this item (“Proposal 3 - 2017 Amended Plan. The shareholders approved the 2017 Amended Plan.”): 18,403,175 for, 2,777,281 against, per its Form 8-K filed 2025-08-27 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 48,708,280 outstanding shares: 38% for, 6% against (43% of the company cast a for/against vote).

The 34 asset managers below cast 99.7% of the shares they voted on this item FOR (1,471,364 for, 3,832 against).

FOR 99.4%
FOR: 1,471,364 (99.4%)AGAINST: 3,832 (0.3%)ABSTAIN: 4,803 (0.3%)
Largest asset managers voting on “TO APPROVE AMENDMENTS TO THE COMPANY'S 2017 EQUITY INCENTIVE PLAN TO, AMONG OTHER THINGS, INCREASE THE NUMBER ” at UroGen Pharma Ltd., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock631,6810 00For
T. Rowe Price266,2980 00For
ARK ETF Trust166,0940 00For
Fidelity164,4870 00For
Equitable38,1690 00For
Lincoln Financial28,9000 00For
SEI25,9600 00For
Global X20,0650 00For
MASTER INVESTMENT PORTFOLIO17,5840 00For
Vanguard14,8510 00For
QUANTITATIVE MASTER SERIES LLC14,6000 00For
Pacific Life12,7760 00For
State Street10,5660 00For
ProShares9,9240 00For
Charles Schwab9,2760 00For
Bridge Builder Trust6,0890 00For
Goldman Sachs6,0610 00For
John Hancock5,7670 00For
Brighthouse10 4,8030Abstain
AIG/SunAmerica4,3930 00For
Calvert03,832 00Against
Nationwide3,1620 00For
ALPS ETF Trust3,0340 00For
Northern Trust3,0310 00For
CLEARWATER INVESTMENT TRUST2,3250 00For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

24. To approve the engagement of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as the Company's auditor until the Company's 2026 annual meeting of shareholders.

AUDIT-RELATED

Meeting held 2025-08-26.

Combines 2 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.6%

The 34 asset managers below cast 99.9% of the shares they voted on this item FOR (1,475,027 for, 169 against).

FOR: 1,475,027 (99.7%)AGAINST: 169 (0.0%)ABSTAIN: 4,803 (0.3%)
Largest asset managers voting on “To approve the engagement of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as ” at UroGen Pharma Ltd., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock631,6810 00For
T. Rowe Price266,2980 00For
ARK ETF Trust166,0940 00For
Fidelity164,4870 00For
Equitable38,1690 00For
Lincoln Financial28,9000 00For
SEI25,9600 00For
Global X20,0650 00For
MASTER INVESTMENT PORTFOLIO17,5840 00For
Vanguard14,8510 00For
QUANTITATIVE MASTER SERIES LLC14,6000 00For
Pacific Life12,7760 00For
State Street10,5660 00For
ProShares9,9240 00For
Charles Schwab9,2760 00For
Bridge Builder Trust6,0890 00For
Goldman Sachs6,0610 00For
John Hancock5,7670 00For
Brighthouse10 4,8030Abstain
AIG/SunAmerica4,3930 00For
Calvert3,8320 00For
Nationwide3,1620 00For
ALPS ETF Trust3,0340 00For
Northern Trust3,0310 00For
CLEARWATER INVESTMENT TRUST2,3250 00For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

25. To approve the amendment and restatement of the Artides of Association of the Company to, among other things, tie ellgibility for shareholder proposals to the requirements under the Israeli Companies Law.

CORPORATE GOVERNANCE

Meeting held 2026-06-22.

100% fund support · no official result

FOR 99.0%

The 10 asset managers below cast 100% of the shares they voted on this item FOR (406,946 for, 0 against).

FOR: 406,946 (99.0%)ABSTAIN: 3,947 (1.0%)
Largest asset managers voting on “To approve the amendment and restatement of the Artides of Association of the Company to, among other things, ” at UroGen Pharma Ltd., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard168,3850 00For
Charles Schwab88,4180 00For
CLEARWATER INVESTMENT TRUST61,2740 00For
NORTHERN LIGHTS FUND TRUST II37,0520 00For
Russell Investments24,8130 00For
Global X17,4620 00For
SEI5,9000 00For
Brighthouse00 3,9470Abstain
Venerable Variable Insurance Trust2,8580 00For
Nationwide7840 00For

Largest UroGen Pharma Ltd. shareholders voting in 2025-2026

Ranked by the number of UroGen Pharma Ltd. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 48,708,280 shares outstanding at the time of that meeting.

Top UroGen Pharma Ltd. shareholders by shares voted, 2025-2026
#Asset manager % of shares outstanding
1RTW INVESTMENTS, LP 9.33%
2American Century 4.18%
3Kynam Capital Management, LP 3.95%
4BlackRock 3.40%
5MENORA MIVTACHIM HOLDINGS LTD. 2.35%
6ORBIMED ADVISORS LLC 1.86%
7MPM BioImpact LLC 1.84%
8DE Shaw 1.84%
9SILVERARC CAPITAL MANAGEMENT, LLC 1.69%
10Fidelity 1.68%

Reported UroGen Pharma Ltd. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

UroGen Pharma Ltd. beneficial owners on record for the 2025-2026 proxy season
Holder % outstanding Disclosure
The Toronto-Dominion Bank 6.71% 13G
BlackRock 5.84% 13F
Morgan Stanley 5.26% 13F
D.E. Shaw 2.10% 13F
State Street 1.79% 13F
Goldman Sachs 1.23% 13F
Geode Capital 1.08% 13F
Vanguard Group 0.90% 13F
Millennium Management 0.76% 13F
Citadel Advisors 0.65% 13F

Percentages above are of 48,708,280 shares outstanding, as reported by UroGen Pharma Ltd. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from UroGen Pharma Ltd.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At UroGen Pharma Ltd.'s 2 shareholder meetings in the 2025-2026 proxy season (held 2025-08-26 and 2026-06-22), 220 asset managers reported how they voted in their SEC Form N-PX filings, covering 3,217 separate fund positions. Their filings are grouped here into 25 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item of the season, voted at the meeting held 2026-06-22 — To approve, on an advisory basis, the compensation of the Company's named executive officers… — FOR was 89% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: UroGen Pharma Ltd.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-23.

UroGen Pharma Ltd. proxy season coverage: 2024-2025 · 2025-2026 (this page).